Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329
Rank in Stocks
#4374
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its... Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Republic of China. Its business activities are structured into two distinct divisions: Chinese Medicine and Western Medicine. The company's operations extend beyond its core offerings to include the production and distribution of Chinese, Western, and biological pharmaceutical items. It also engages in the wholesale and retail trade of medicines, biochemical pharmaceutical products, and everyday consumer goods, in addition to managing hospitals. Furthermore, Tianjin Pharmaceutical Da Ren Tang provides a comprehensive suite of services such as logistics, inventory management, equipment installation, and drug processing. It also offers pharmaceutical inspection, testing, and advisory services. In terms of its commercial model, the company supplies its proprietary branded medicinal products directly to wholesalers. Conversely, it acquires pharmaceuticals marketed under other brands from distributors, subsequently reselling these to other wholesale clients. Established in 1992 and based in Tianjin, People's Republic of China, the company was previously known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited before adopting its current name in May 2022.
Share Price
$6.17
Market Cap
$3.52B
Change (1 day)
-0.05%
Change (1 year)
-1.86%
Country
CN
Trade Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
Category
Healthcare
P/E ratio for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329)
P/E ratio as of October 2026 TTM: 37.37
According to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 37.37. At the end of 2024 the company had a P/E ratio of 10.64.
P/E ratio history for Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited from 2001 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 37.37 | 126.89% |
| 2025 | 16.47 | 54.78% |
| 2024 | 10.64 | -59.53% |
| 2023 | 26.29 | 1.26% |
| 2022 | 25.96 | -17.31% |
| 2021 | 31.40 | 54.24% |
| 2020 | 20.36 | 19.50% |
| 2019 | 17.04 | 4.75% |
| 2018 | 16.26 | -32.78% |
| 2017 | 24.19 | -23.66% |
| 2016 | 31.69 | -10.14% |
| 2015 | 35.27 | 10.93% |
| 2014 | 31.79 | 20.92% |
| 2013 | 26.29 | 48.82% |
| 2012 | 17.67 | -37.71% |
| 2011 | 28.36 | -22.02% |
| 2010 | 36.38 | 17.88% |
| 2009 | 30.86 | 65.68% |
| 2008 | 18.63 | -130.45% |
| 2007 | -61.16 | 1,134.91% |
| 2006 | -4.95 | -127.87% |
| 2005 | 17.77 | -39.63% |
| 2004 | 29.44 | 10.44% |
| 2003 | 26.66 | -36.86% |
| 2002 | 42.22 | -45.27% |
| 2001 | 77.13 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| 55.58 | 48.72% |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -6.45% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.